Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial

Hosing, Chitra; McLaughlin, Eric; Braunstein, Zachary; Valdez, Benigno C.; Wei, Lai; Popat, Uday; Andersson, Börje S.; Vasu, Sumithira; Larkin, Karilyn; Jaglowski, Samantha; Penza, Sam; Saad, Ayman; Choe, Hannah; Wall, Sarah; Cash, Alex; Nakkula, Robin J.; Champlin, Richard E.; Lima, Marcos J.G. de; Lee, Dean A.; Brammer, Jonathan E.

doi:10.1182/blood-2022-169336

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phase I/II trials on romidepsin, conducted in Japan, found that romidepsin caused few critical side effects other than temporary anemia, and despite its single-agent nature, the overall response rate (ORR) was 25% (15% complete response [CR] rate) [ 6 ]; romidepsin demonstrated similar efficacy and tolerability for R/R PTCL regardless of age [ 7 ]. Although romidepsin maintenance after allogeneic hematopoietic stem cell transplantation (HSCT) for AITL was promising [ 8 ], no clinical trials have examined consolidation therapies following salvage chemotherapy in elderly transplant-ineligible patients with R/R PTCL. Although a standard treatment has not been established in R/R PTCL and the endpoint in most clinical trials was ORR [ 9 ] rather than OS, future developments in treatment may be facilitated by introducing romidepsin.…”

Section: Introductionmentioning

confidence: 99%

Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Yamasaki,

Iida,

Saito

et al. 2024

Hematology Reports

View full text Add to dashboard Cite

Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains controversial. The objective of this study was to characterize the safety and efficacy of romidepsin as consolidation therapy after gemcitabine, dexamethasone, and cisplatin (GDP) therapy (GDPR). This study of patients treated between March 2019 and March 2021 was registered with the Japan Registry of Clinical Trials (registration number: jRCT0000000519). If complete response, partial response, or stable disease was confirmed after 2–4 GDP cycles, romidepsin was administered every 4 weeks for 1 year. Seven patients with relapsed/refractory (R/R) PTCL (T-follicular helper phenotype [n = 1] and angioimmunoblastic T-cell lymphoma [n = 6]) were included in this prospective study (PTCL-GDPR). After a median follow-up of 34 months of patients in PTCL-GDPR, the 2-year overall survival rate was 71%, and the overall response rate after treatment was 57%. Common adverse events in patients with PTCL-GDPR included hematological toxicities such as neutropenia, which improved with supportive treatment. There were no treatment-related mortalities. GDPR might be safe and effective in elderly transplant-ineligible patients with R/R PTCL; however, further investigation is required.

show abstract